Skip to main content
. 2016 Apr 29;7(24):35894–35916. doi: 10.18632/oncotarget.9116

Figure 4. Specific targeting to CD90+ LCSCs with CD90-Rh/TMs.

Figure 4

A. Internalization of control group, CD90-Rh/TMs group, Rh group, Rh/TMs group and CD90− Huh7 group detected by confocal microscopy, the bar = 20μm. B. The fluorescence intensity of Rh detected by confocal microscopy (mean ± SD, n = 3). C. Binding and internalization detected by flow cytometry of DMEM/F12 (control group), CD90-Rh/TMs (CD90- Rh/TMs group), free Rh(Rh group), Rh/TMs(Rh/TMs group) and CD90− Huh7 cells incubated with CD90-Rh/TMs(CD90− Huh7 group). D. Prussian blue staining of CD90+ LCSCs incubated with DMEM/F12 (control group), CD90@TMs (CD90@TMs group), pure Fe3O4 (Fe3O4 group), TMs (TMs group) and CD90−Huh7 cells incubated with CD90@TMs (CD90− Huh7 group), the bar = 20μm. E. T2-weighted MRI images of control group, CD90@TMs group, Fe3O4 group, TMs group and CD90− Huh7 group. F. T2 relaxation time of control group, CD90@TMs group, Fe3O4 group, TMs group and CD90− Huh7 group (mean ± SD, n = 3). *P > 0.05; **P < 0.05. Abbreviations: Rh, Lissamine rhodamine; TMs, thermosensitive magnetoliposomes; DMEM/F12, Dulbecco's Modified Eagle Media: Nutrient Mixture F-12; CD90, cluster of differentiation 90.